Back

Vincere wins $2.7 million NIH grant for kidney injury drug studies

Verifying
  • Vincere Biosciences received an NIDDK SBIR Phase II grant for a kidney-focused USP30 inhibitor.
  • The award totals $2.7 million over two years and funds IND-enabling safety studies.
  • Vincere separately advances a CNS-penetrant USP30 inhibitor for Parkinson’s disease.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Vincere wins $2.7 million NIH grant for kidney injury drug studies - CoinPost Terminal